Luma Group

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

Through our deep scientific and industry network we are able to identify transformative life science investments in under-ventured regions of the US and UK, building companies from scratch to create value and shared success. Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our investors. We believe in working closely with the management of our portfolio companies to drive the translation of their research into world-class businesses. Our global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders. This strong network contributes significantly to the growth and development of our portfolio companies.

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them